Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$101.69
-1.7%
$96.00
$77.10
$163.71
$5.91B0.82741,036 shs962,895 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$248.05
-1.2%
$268.15
$148.00
$310.00
$9.72B0.47453,616 shs321,451 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$29.95
-1.1%
$29.13
$23.69
$31.72
$13.26B0.69808,769 shs987,102 shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$92.58
-1.2%
$93.85
$89.22
$116.71
$18.53B0.711.81 million shs1.99 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%+2.00%+11.25%+20.53%-15.00%
Penumbra, Inc. stock logo
PEN
Penumbra
0.00%-2.18%-3.20%-4.95%+38.35%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.00%+0.05%-0.07%+17.72%+12.87%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.00%+2.42%+1.29%-10.49%-13.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Corporation stock logo
GKOS
Glaukos
4.5312 of 5 stars
4.41.00.04.43.51.70.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.6563 of 5 stars
3.43.00.03.72.72.51.9
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
3.0504 of 5 stars
1.05.02.50.00.60.04.4
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
4.881 of 5 stars
3.23.02.53.73.02.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6732.43% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4021.91% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$28.00-6.51% Downside
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.30
Hold$111.3320.26% Upside

Current Analyst Ratings Breakdown

Latest GKOS, ZBH, SNN, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$115.00 ➝ $101.00
5/7/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$140.00 ➝ $125.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$101.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$138.00 ➝ $115.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $104.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$119.00 ➝ $104.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$125.00 ➝ $112.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $95.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$128.00 ➝ $105.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$113.00 ➝ $98.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M15.15N/AN/A$13.91 per share7.31
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.04$2.85 per share86.97$29.99 per share8.27
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$5.81B2.26$3.12 per share9.59$12.04 per share2.49
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$7.68B2.39$13.04 per share7.10$62.67 per share1.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06234.0149.512.243.41%11.14%8.40%7/29/2025 (Estimated)
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$412M$2.1613.8714.980.93N/AN/AN/A8/5/2025 (Estimated)
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$903.70M$4.5220.4810.442.1711.86%12.73%7.34%8/6/2025 (Estimated)

Latest GKOS, ZBH, SNN, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
5/5/2025Q1 2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.77$1.81+$0.04$0.91$1.89 billion$1.91 billion
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.892.97%N/A41.20%N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.961.04%N/A21.24%N/A

Latest GKOS, ZBH, SNN, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/30/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.241.03%6/26/20256/26/20257/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.89
1.33
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.53
2.44
1.46

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
6.40%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.48 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million36.79 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
17,349437.97 million433.59 millionOptionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
17,000197.85 million196.46 millionOptionable

Recent News About These Companies

ZBH - Zimmer Biomet Holdings Inc Key Metrics | Morningstar
ZBH - Zimmer Biomet Holdings Inc Chart | Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Glaukos stock logo

Glaukos NYSE:GKOS

$101.69 -1.81 (-1.75%)
Closing price 03:59 PM Eastern
Extended Trading
$101.50 -0.19 (-0.18%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Penumbra stock logo

Penumbra NYSE:PEN

$248.05 -3.01 (-1.20%)
Closing price 03:58 PM Eastern
Extended Trading
$246.00 -2.05 (-0.83%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$29.95 -0.33 (-1.09%)
Closing price 03:59 PM Eastern
Extended Trading
$29.96 +0.00 (+0.02%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$92.58 -1.09 (-1.16%)
Closing price 03:59 PM Eastern
Extended Trading
$92.19 -0.39 (-0.42%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.